

*Contains Nonbinding Recommendations*

# **Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers**

---

## **Guidance for Industry and Food and Drug Administration Staff**

**Document issued on August 29, 2024.**

**The draft of this document was issued on December 9, 2022.**

For questions about this document regarding CDRH-regulated devices, contact the Office of Regulatory Programs (ORP)/Division of Regulatory Programs 3 (DRP3)/Medical Device Reporting (MDR) Team at [MDRPolicy@fda.hhs.gov](mailto:MDRPolicy@fda.hhs.gov). For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010, or by email at [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov).



**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health  
Center for Biologics Evaluation and Research**

# Preface

## Public Comment

You may submit electronic comments and suggestions at any time for Agency consideration to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852-1740. Identify all comments with the docket number FDA-2022-D-2873. Comments may not be acted upon by the Agency until the document is next revised or updated.

## Additional Copies

### CDRH

Additional copies are available from the Internet. You may also send an email request to [CDRH-Guidance@fda.hhs.gov](mailto:CDRH-Guidance@fda.hhs.gov) to receive a copy of the guidance. Please include the document number GUI00021007 and complete title of the guidance in the request.

### CBER

Additional copies are available from the Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach, and Development (OCOD), 10903 New Hampshire Ave., WO71, Room 3128, Silver Spring, MD 20993-0002, or by calling 1-800-835-4709 or 240-402-8010, by email, [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov), or from the Internet at <https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>.

## **Table of Contents**

I.	Introduction.....	1
II.	Background.....	2
III.	Principles of Voluntary Malfunction Summary Reporting.....	4
IV.	Voluntary Malfunction Summary Reporting Program Eligibility and Scope .....	5
	A. Product Code Eligibility.....	5
	(1) Periodic Evaluation.....	5
	(2) Eligibility Requests.....	6
	B. Event Types and Reporters Not Covered by the VMSR Program.....	7
V.	VMSR Program Conditions.....	7
	A. Individual Reporting Conditions.....	7
	(1) Reportable malfunction is associated with a 5-day report.....	8
	(2) A reportable malfunction is the subject of certain device recalls.....	8
	(3) FDA has determined that individual MDR reporting is necessary to address a public health issue.....	9
	(4) FDA has determined that a device manufacturer may not report in summary reporting format.....	10
	(5) A new type of reportable malfunction occurs for a device.....	10
	B. Supplemental Reports .....	11
	C. Summary Reporting Instructions .....	11
	(1) Instructions Using Form FDA 3500A .....	12
	(2) Reporting Schedule and Logistics .....	13
	Appendix: Example of Malfunction Summary Reports .....	14

# Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers

## Guidance for Industry and Food and Drug Administration Staff

*This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.*

### I. Introduction

The Food and Drug Administration (FDA) is issuing this final guidance document to help manufacturers better understand and use the Voluntary Malfunction Summary Reporting (VMSR) Program. It is intended to further explain, but not change, the conditions of the VMSR Program.

This guidance describes and clarifies several aspects of the VMSR Program, including the FDA's approach to determining the eligibility of product codes for the program and the conditions for submitting medical device reports (MDRs) for device malfunctions in summary format under the program. Consistent with the goals outlined in the [Medical Device User Fee Amendments of 2017 \(MDUFA IV\) Commitment Letter](#), the VMSR Program is intended to streamline reporting of device malfunctions. The program began in 2018 when FDA issued a notification in the Federal Register of an order granting an alternative under 21 CFR 803.19 that permits manufacturers of devices in eligible product codes to report certain device malfunction MDRs in summary form on a quarterly basis, subject to the conditions of the alternative (2018 Notice, [83 FR 40973](#)). On August 29, 2024 FDA issued a notification in the Federal Register, announcing a minor, technical modification to the VMSR Program alternative granted under 21 CFR 803.19, to align with the most current version of Form FDA 3500A and with current adverse event codes (Modification Notice, [89 FR 70096](#)). This guidance is consistent with that modification.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of

## *Contains Nonbinding Recommendations*

the word *should* in Agency guidances means that something is suggested or recommended, but not required.

## **II. Background**

Each year, FDA receives over two million MDRs of suspected device-related deaths, serious injuries, and malfunctions. The MDR Program is one of the postmarket surveillance tools that FDA uses to monitor device performance, detect potential device-related safety issues, and contribute to benefit-risk assessments.<sup>1</sup> Malfunction reports represent most of the MDRs received by FDA on an annual basis. As part of FDA's postmarket surveillance for devices, the Agency reviews the MDRs submitted by both mandatory and voluntary reporters.

FDA has determined that for many devices, it is appropriate to permit manufacturers to submit malfunction summary reports on a quarterly basis, for certain malfunctions related to devices with certain product codes, instead of individual, 30-day malfunction reports. FDA's VMSR Program is intended to yield benefits for FDA, the public, and manufacturers, such as increasing transparency for the public, helping FDA to process certain malfunction reports more efficiently, allowing both FDA and the public to identify malfunction trends more readily, and reducing the burden on manufacturers.

MDR requirements for manufacturers are set forth in section 519 of the Federal Food, Drug, and Cosmetic (FD&C) Act and 21 CFR Part 803. Among other things, 21 CFR Part 803 requires that a manufacturer submit a report of an individual adverse event when it becomes aware of information, from any source, that reasonably suggests that one of its marketed devices malfunctioned and the malfunction of the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur (21 CFR 803.10(c)(1) and 803.50(a)(2)). Throughout this guidance document, FDA refers to such malfunctions as "reportable malfunctions" or "reportable malfunction events." Under 21 CFR Part 803, such reports generally must be submitted to FDA within 30 calendar days after the day the manufacturer becomes aware of the reportable malfunction event (21 CFR 803.10(c)(1) and 803.50). Under some circumstances an MDR is required to be submitted within 5 workdays after the day the manufacturer becomes aware of the need to submit such a report (see 21 CFR 803.10(c)(2) and 803.53).

The FDA Amendments Act of 2007 (FDAAA<sup>2</sup>) amended section 519(a) of the FD&C Act related to the reporting of device malfunctions. FDAAA did not alter the malfunction reporting requirements for class III devices and those class II devices that are permanently implantable, life supporting, or life sustaining. Under section 519(a)(1)(B)(i) of the FD&C Act, as amended by FDAAA, manufacturers of such devices must continue to submit malfunction reports in accordance with 21 CFR Part 803 (or successor regulations), unless FDA grants an exemption or variance from, or an alternative to, a requirement under such regulations pursuant to 21 CFR 803.19. FDAAA also amended the FD&C Act to require that manufacturers submit malfunction MDRs for class I and those class II devices that are not permanently implantable, life supporting,

---

<sup>1</sup> For general information on the MDR Program, see FDA's website on [Medical Device Reporting \(MDR\): How to Report Medical Device Problems](#).

<sup>2</sup> Pub. L. 110-85.

### *Contains Nonbinding Recommendations*

or life sustaining—other than any type of class I or II device that FDA has, by notice, published in the Federal Register or by letter to the person who is the manufacturer or importer of the device, indicated should be subject to Part 803 in order to protect the public health—in accordance with criteria established by FDA. The criteria require those reports to be in summary form and made on a quarterly basis. See section 519(a)(1)(B)(ii) of the FD&C Act. In the Federal Register of March 8, 2011 ([76 FR 12743](#)), FDA explained that, pending further notice from the Agency, all class I devices and those class II devices that are not permanently implantable, life supporting, or life sustaining would remain subject to individual reporting requirements under Part 803 to protect the public health, pursuant to section 519(a)(1)(B)(i)(III) of the FD&C Act. Consequently, unless granted an exemption, variance, or alternative, manufacturers of those devices have continued to be required to submit individual malfunction reports under Part 803. FDA began a pilot program in 2015 for the submission of MDRs of certain malfunctions in a summary format on a quarterly basis ([80 FR 50010](#)).

In the MDUFA IV Commitment Letter, FDA committed to streamlining MDR requirements for malfunction reporting.<sup>3</sup> To help meet the MDUFA IV commitment, FDA issued a notification in 2017 ([82 FR 60922](#)) outlining FDA’s proposal to grant an alternative under 21 CFR 803.19 to permit manufacturer reporting of certain device malfunctions in summary format on a quarterly basis, subject to certain conditions, and requested public comment. FDA granted that alternative in 2018 to manufacturers of devices in certain product codes and provided notice of an order granting that alternative in the Federal Register (2018 Notice, [83 FR 40973](#)).

FDA implemented the VMSR Program only after the Agency had conducted the 2015 pilot program that demonstrated the value of the program to public health, better use of Agency resources, and promotion of public transparency.

As explained when it proposed the VMSR Program ([82 FR 60922](#)), and consistent with our VMSR Program experience to date, FDA believes that bundling “like events” together into a single summary report description has benefits for manufacturers, FDA, and the public. For many manufacturers, we expect this approach will greatly reduce the volume of reports that the manufacturer needs to submit to FDA. As more information is received in a streamlined manner, it can facilitate a more efficient understanding by FDA of malfunction issues. For the public, summary reports may make malfunction event trends for a particular device more readily transparent. We believe increased manufacturer participation in the program will enhance these benefits.

---

<sup>3</sup> See 163 CONG. REC. S4729-S4736 (daily ed. August 2, 2017) (Food and Drug Administration User Fee Reauthorization), also available at FDA webpage on [Medical Device User Fee Amendments 2017 \(MDUFA IV\)](#).

### **III. Principles of Voluntary Malfunction Summary Reporting**

In the 2018 Notice, FDA identified the following overarching principles for summary reporting of malfunctions under the VMSR Program:

1. The collection of information in summary format should allow FDA to collect sufficient detail to understand reportable malfunction events.
2. To increase efficiency, summary malfunction reporting should occur in a common format for the electronic reporting system used.
3. Information about reportable malfunctions should be transparent to FDA and to the public, regardless of whether the information is reported as an individual MDR or a summary report.<sup>4</sup> Information contained in a summary malfunction report that is protected from public disclosure under applicable disclosure laws is redacted prior to release of the report.
4. Manufacturers should communicate information regarding an imminent hazard<sup>5</sup> at the earliest time possible.
5. Summary reporting is meant to streamline the process of reporting malfunctions. It does not change regulatory requirements for MDR-related investigations or recordkeeping by manufacturers. For example, manufacturers participating in the VMSR Program remain subject to requirements for establishing and maintaining MDR event files under 21 CFR 803.18. In addition, under the Quality System regulation, manufacturers must evaluate, review, and investigate any complaint that represents an MDR reportable event (see 21 CFR 820.198).<sup>6</sup>
6. Summary reporting information should not be duplicative of information received through other MDR reporting processes.

---

<sup>4</sup> Consistent with this principle, summary reports submitted by manufacturers under the VMSR Program are made available to the public in the [Manufacturer and User Facility Device Experience \(MAUDE\) database](#). For more information about FDA's procedures for disclosing information submitted under 21 CFR Part 803, see 21 CFR 803.9.

<sup>5</sup> For the purposes of this overarching principle and as explained in the 2018 Notice ([83 FR 40793](#)), FDA intends "imminent hazard" to capture situations in which a device poses a significant risk to health and creates a public health situation that should be addressed immediately to prevent injury.

<sup>6</sup> On February 2, 2024, FDA issued a final rule amending the device quality system (QS) regulation, 21 CFR part 820, to align more closely with international consensus standards for devices and making conforming amendments to 21 CFR part 4 ([89 FR 7496](#)). This final rule will take effect on February 2, 2026. Once in effect, this rule will withdraw the majority of the current requirements in part 820 and incorporate by reference the 2016 edition of the International Organization for Standardization (ISO) 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, in part 820. As stated in the final rule, the requirements in ISO 13485 are, when taken in totality, substantially similar to the requirements of the current part 820, providing a similar level of assurance in a firm's quality management system and ability to consistently manufacture devices that are safe and effective and otherwise in compliance with the FD&C Act. When the final rule takes effect, FDA will also update the references to provisions in 21 CFR part 820 in this guidance to be consistent with that rule.

## **IV. Voluntary Malfunction Summary Reporting Program Eligibility and Scope**

The VMSR Program permits manufacturers of devices within eligible product codes to report certain device malfunction MDRs in summary form quarterly, as an alternative to submitting individual MDRs for reportable malfunction events. Manufacturers may “self-elect” to participate in the VMSR Program by submitting summary malfunction reports for eligible product codes, and do not need to submit a separate application to FDA to participate. As participation in the VMSR Program is voluntary, applicants may choose to leave the program at any time. Upon leaving the VMSR Program, manufacturers must resume submitting individual, 30-day malfunction reports in compliance with 21 CFR 803.50 and 803.52 and update their MDR procedure as needed to comply with 21 CFR 803.17.

The VMSR Program helps enhance the FDA’s capacity to effectively monitor the safety and effectiveness of devices. The VMSR Program’s conditions help ensure that manufacturers submit sufficient information to allow FDA to detect potential safety issues and identify malfunction trends, while the summary reports provide information on malfunctions in a more efficient format. The program thus enables FDA to be more effective in its device safety oversight. The following sub-sections are intended to explain the factors FDA generally considers when determining if a product code is eligible for the VMSR Program and to clarify event types that are not covered by the VMSR Program. Further clarification on the reporting conditions of the program are discussed under Section V.

### **A. Product Code Eligibility**

When FDA implemented the VMSR Program in 2018, the Agency evaluated all device product codes, for all device classes, to determine program eligibility, including product codes for device-led combination products. As noted, when FDA began the VMSR Program, product codes that have been in existence for fewer than two years generally are not eligible, unless the new product code was created solely for administrative reasons.<sup>7</sup> In FDA’s experience, this two-year period is important for having more timely, detailed information to monitor malfunction events. FDA continues to evaluate new product codes after they have been in existence for two years to determine whether it is appropriate for those product codes to be eligible for the VMSR Program. FDA also periodically evaluates ineligible product codes for eligibility changes.

#### **(1) Periodic Evaluation**

The FDA intends to periodically assess and update the eligibility of product codes for the VMSR Program. As part of determining eligibility of product codes, FDA intends to consider the device’s benefit-risk profile and available postmarket safety information, particularly related to device malfunctions. The Agency generally considers whether quarterly, summary reporting of device malfunctions, in accordance with the conditions of the VMSR Program, would allow FDA to timely identify potential new or increased safety concerns for devices within the product

---

<sup>7</sup> 2018 Notice ([83 FR 40973](#)).



## *Contains Nonbinding Recommendations*

code at issue. If FDA determines that a product code is eligible, FDA intends to update the [Product Classification Database](#) accordingly. In addition, FDA intends to provide information regarding the list of eligible product codes for the VMSR Program on the VMSR webpage.<sup>8</sup>

In analyzing available postmarket safety information for devices within a certain product code, the Agency also intends to consider, among other things, the frequency of reported serious injuries and deaths, the number of 5-day reports, and whether the product code has any class I or II recalls. The Agency may also consider the types of malfunctions that occur in a given product code, the complexity of those malfunctions, and the ability for FDA to understand their root cause. FDA may also consider whether the product code is associated with recent, ongoing, or potential public health issues that may necessitate the detail and frequency of individual malfunction reporting for FDA to identify and better characterize new or persistent safety issues. When a public health issue necessitates close monitoring of individual adverse events associated with certain devices, the Agency may determine that summary reporting under the VMSR Program is not appropriate for product codes for those devices. For example, FDA has determined that certain reusable devices may have a high risk of infection if they are not adequately reprocessed. Devices listed in Appendix E of the FDA guidance document, “[Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling](#),” are examples of device types associated with such risks, and FDA has determined for these product codes that summary reporting is not appropriate.

FDA’s eligibility determinations are intended to follow the overarching principles of the VMSR Program described in Section III above, to help ensure that summary reporting of malfunctions for all eligible product codes allows FDA to collect sufficient information to understand the reported events, that information can be provided in a common format and is transparent to FDA and to the public, that imminent hazards will be communicated at the earliest time possible, and that summary reporting for devices in any eligible product code streamlines the process of reporting malfunctions.

### **(2) Eligibility Requests**

Manufacturers may send a request under 21 CFR 803.19(b) for a product code or multiple product codes to be considered for eligibility in the VMSR Program and for manufacturers of devices within such product code(s) to be granted the same summary reporting alternative for reportable malfunction events associated with those devices. FDA intends to periodically review manufacturer requests and update the eligibility of product codes for the VMSR Program based on requests received. In addition, as noted above, FDA intends to provide information regarding the list of eligible product codes for the VMSR Program on the VMSR webpage.<sup>9</sup>

For requests emailed to FDA at [MDRPolicy@fda.hhs.gov](mailto:MDRPolicy@fda.hhs.gov), manufacturers should submit the following information:

- The firm’s name, address, registration number;
- The contact person’s name, telephone number, and email address;

---

<sup>8</sup> For more information on the VMSR Program and eligible product codes, please see FDA’s webpage on [Voluntary Malfunction Summary Reporting Program](#).

<sup>9</sup> For more information on the VMSR Program and eligible product codes, please see FDA’s webpage on [Voluntary Malfunction Summary Reporting Program](#).

## *Contains Nonbinding Recommendations*

- Complete device identification and description, including product code and review panel;
- A complete statement of the request and justification for the request, including a discussion of known information related to the product code's benefit-risk profile and postmarket safety, and why individual malfunction reporting is not necessary; and
- As part of the justification for the request, a manufacturer should provide a copy of any prior FDA correspondence (including the references to the Document ID #) regarding device eligibility status and describe any actions taken to address any issues noted in prior FDA correspondence regarding device eligibility for participation in the VMSR Program.

### **B. Event Types and Reporters Not Covered by the VMSR Program**

As described above, the VMSR Program is generally available for manufacturers of devices within eligible product codes. However, the following types of MDR reportable events and entities subject to MDR reporting requirements are outside the scope of the VMSR Program alternative granted under 21 CFR 803.19:

- Reportable deaths and serious injuries;<sup>10</sup>
- A reportable malfunction is associated with a 5-day report, as required in 21 CFR 803.53; and
- Importers and device user facilities, because 21 CFR Part 803 does not require either entity to report malfunctions to FDA.<sup>11</sup>

## **V. VMSR Program Conditions**

### **A. Individual Reporting Conditions**

As previously discussed, manufacturers participating in the VMSR Program submit summary malfunction reports under an alternative to certain MDR reporting requirements that FDA has granted to manufacturers of devices within eligible product codes. When FDA grants such modifications to the MDR reporting requirements, we may impose other reporting requirements to ensure the protection of public health (21 CFR 803.19(c)). Accordingly, FDA has imposed

---

<sup>10</sup> See section III.A of the Modification Notice. The alternative granted under 21 CFR 803.19 to manufacturers participating in the VMSR Program does not alter the requirement that reportable deaths and serious injuries must be reported to FDA within the mandatory 30-calendar day timeframe, under 21 CFR 803.50 and 803.52, or within the 5-work day timeframe under 21 CFR 803.53, as applicable. Thus, if a manufacturer participating in the VMSR Program becomes aware of information reasonably suggesting that a device that it markets may have caused or contributed to a death or serious injury, then the manufacturer must submit an individual MDR for that event because it involves a reportable death or serious injury.

<sup>11</sup> See section III of the Modification Notice. Importers are required to report malfunctions to the manufacturer under 21 CFR 803.40(b). Unlike manufacturers and importers, device user facilities are not required under 21 CFR Part 803 to submit malfunction reports to any entity.

## *Contains Nonbinding Recommendations*

several conditions that manufacturers must follow if they elect to participate in the VMSR Program under the alternative.<sup>12</sup> These include conditions for “individual reporting,” submission of supplemental reports, and the format and submission schedule for summary reports. We describe and clarify these conditions in the following subsections.

FDA explained in the 2018 Notice that individual reporting is necessary under certain circumstances for devices within product codes that are otherwise eligible for the VMSR Program. For certain individual reporting conditions, as described below, manufacturers are responsible for identifying whether the condition applies. For other individual reporting conditions, FDA will notify manufacturers that individual reporting is necessary. Such notifications will explain why FDA determined that individual reporting is necessary and as appropriate, the steps necessary for a manufacturer to resume summary, quarterly reporting.

Manufacturers participating in the VMSR Program must submit individual reports in the following circumstances, in accordance with the conditions of the program:

### **(1) Reportable malfunction is associated with a 5-day report**

Under 21 CFR 803.53(a), a manufacturer must submit a 5-day report if it becomes aware of an MDR reportable event that necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. After submitting a 5-day report required under 21 CFR 803.53(a), all subsequent reportable malfunctions of the same nature that involve substantially similar devices<sup>13</sup> must be submitted as individual MDRs pursuant to 21 CFR 803.50 and 803.52, unless FDA notifies the manufacturer that the issue has been resolved to FDA’s satisfaction and individual reports are no longer required. Summary reporting of malfunctions may then resume on the regularly scheduled summary reporting cycle.<sup>14</sup> Submission of reportable malfunctions associated with 5-day reports in this manner will assist FDA in monitoring the time course and resolution of the issue presenting an unreasonable risk of substantial harm to the public health.

### **(2) A reportable malfunction is the subject of certain device recalls**

When a device is the subject of a recall involving the correction or removal of the device to address a malfunction and that correction or removal is required to be reported to FDA under 21 CFR Part 806 (this includes class I and class II recalls, but not class III recalls),<sup>15</sup> all reportable malfunction events of the same nature<sup>16</sup> that involve the same device or a similar device marketed by the same manufacturer must be submitted as individual MDRs in accordance with

---

<sup>12</sup> Throughout this section, FDA uses the term “must” to describe conditions of the VMSR Program consistent with the Modification Notice, as well as to describe statutory or regulatory requirements. The Modification Notice republished the conditions that manufacturers must follow if they choose to participate in the VMSR Program with the minor, technical changes described in section II of that notice incorporated.

<sup>13</sup> For example, and as explained in the 2018 Notice, a “substantially similar” device could be a device that is the same except for certain performance characteristics or a device that is the same except for certain cosmetic differences in color or shape. See 2018 Notice, section II.C ([83 FR 40973](#)).

<sup>14</sup> Modification Notice, section III.B.1.

<sup>15</sup> See 21 CFR 7.3(m) for the definition of each numerical recall classification.

<sup>16</sup> By “malfunction events of the same nature,” and as explained in the 2018 Notice, FDA means additional reportable malfunction events involving the same malfunction that prompted the recall.

### *Contains Nonbinding Recommendations*

21 CFR 803.50 and 803.52 until the date that the recall is terminated by FDA.<sup>17</sup> After the recall is terminated, summary reporting may resume on the regularly scheduled summary reporting cycle, unless after the recall event, FDA has revoked the VMSR Program alternative with respect to that device product code.

The requirement to submit individual reports under this condition is triggered on the date that the manufacturer submits a report of a correction or removal required under 21 CFR Part 806 (or the date that the manufacturer submits a report of the correction or removal under 21 CFR Part 803 or 21 CFR Part 1004 instead, as permitted under 21 CFR 806.10(f)). This will allow FDA to monitor the frequency of reportable malfunctions associated with the recall and effectiveness of the recall strategy.

If a manufacturer becomes aware of reportable malfunction events before the date that the requirement to submit individual reports is triggered and a summary report for those events has not yet been submitted to FDA, then the manufacturer must submit any of those malfunction events related to the recall in a summary MDR format within 30 calendar days of submitting the required report of correction or removal. In the summary MDR, the manufacturer must include a check box of recall in the “If Remedial Action Initiated, Check Type” of the electronic Form FDA 3500A.<sup>18</sup>

### **(3) FDA has determined that individual MDR reporting is necessary to address a public health issue**

If FDA determines that individual malfunction reports are necessary to provide additional information and more rapid reporting for an identified public health issue involving certain devices, manufacturers must submit reportable malfunction events for those devices as individual MDRs pursuant to 21 CFR 803.50 and 803.52. Such determination may apply to all reportable malfunctions for a particular device or multiple devices (e.g., all devices within an eligible product code); such determination may also apply to only certain types of malfunctions for the particular device(s), depending on the scope of the public health issue.

FDA will provide written notification to manufacturers of relevant devices that individual MDR submissions are necessary. FDA will also provide further written notice when manufacturers of those devices may resume participation in summary malfunction reporting. If a manufacturer becomes aware of reportable malfunction events before receiving written notice to submit such events individually, and a summary report for those events has not yet been submitted to FDA, then the manufacturer must submit malfunction events for the identified devices to FDA within 30 calendar days of receiving notification from FDA.<sup>19</sup> For such reportable malfunctions, the events may generally be submitted as summary reports, but if there are circumstances in which FDA specifically recommends individual reports because of the nature of the public health issue, the agency intends to specify that in its written notification.

Below, we have provided examples of situations where FDA has determined that individual MDR reporting is necessary to address a public health issue, and summary reporting would not

---

<sup>17</sup> See 21 CFR 7.55 (describing when recalls will be terminated).

<sup>18</sup> Modification Notice, section III.B.2.

<sup>19</sup> Modification Notice, section III.B.3.

## *Contains Nonbinding Recommendations*

be appropriate. However, public health issues are not uniform, can be unpredictable, and may arise in various ways; the following are examples, and there may be other scenarios not described below where individual malfunction reports are necessary to address or evaluate a public health issue. As illustrated below, this individual reporting condition may apply to reporting for a particular device or multiple devices of the same type, or only to certain types of malfunctions for that device type.

### Examples of Circumstances in which FDA has Determined Individual Malfunction Reporting is Necessary:

- Where FDA has determined that certain reusable devices that fall within eligible product codes may have a high risk of infection if they are not adequately reprocessed, which FDA considers a public health issue.
- Where there is an ongoing safety signal or other safety-related investigation of a known or potential public health concern.
- Where root causes of malfunction events are not well understood.

#### **(4) FDA has determined that a device manufacturer may not report in summary reporting format**

FDA may determine that a specific manufacturer may no longer participate in the VMSR Program for reasons including, but not limited to, failure to comply with applicable MDR requirements under 21 CFR Part 803, failure to follow the conditions of the VMSR Program, or the need to monitor a public health issue such as an investigation into safety-related issues at a specific manufacturer's establishment.<sup>20</sup>

FDA will provide written notification to the device manufacturer to submit individual malfunction reports in compliance with 21 CFR 803.50 and 803.52. The requirement to submit individual reports under this condition is triggered on the date the manufacturer receives the written notification from FDA. If a manufacturer became aware of reportable malfunction events before the date that the requirement to submit individual reports is triggered under this condition and a summary report for those events has not yet been submitted to FDA, then the manufacturer must submit those malfunction events to FDA within 30 calendar days of receiving notification from FDA.<sup>21</sup> For such reportable malfunctions, the events may generally be submitted as summary reports, but if there are circumstances in which FDA specifically recommends individual reports because of the nature of the public health issue, the agency intends to specify that in its written notification.

#### **(5) A new type of reportable malfunction occurs for a device**

If a manufacturer becomes aware of information reasonably suggesting that a reportable malfunction event has occurred for a device that the manufacturer markets and the reportable malfunction is a new type of malfunction that the manufacturer has not previously reported to FDA for that device, then the manufacturer must submit an individual report for that reportable malfunction in compliance with 21 CFR 803.50 and 803.52. After the manufacturer submits this initial individual report, subsequent malfunctions of this type may be submitted in summary form

---

<sup>20</sup> Modification Notice, section III.B.4.

<sup>21</sup> Modification Notice, section III.B.4.

## *Contains Nonbinding Recommendations*

according to the quarterly reporting schedule described in Section V.C.2 of this guidance document, unless another individual reporting condition applies.<sup>22</sup>

### **B. Supplemental Reports**

Under the VMSR Program, in general, if a manufacturer becomes aware of information required in a malfunction summary report that the manufacturer did not submit to FDA because the information was not previously known or was not available when the manufacturer submitted the initial summary malfunction report, then the manufacturer must submit the supplemental information to FDA in an electronic format in accordance with 21 CFR 803.12(a). Supplemental information must be submitted by manufacturers to FDA by the submission deadline described in Table 1—Summary Malfunction Reporting Schedule of the Modification Notice,<sup>23</sup> which we provide below in Section V.C.2 of this guidance document. Supplemental information must be submitted by the applicable deadline according to the date on which the manufacturer becomes aware of the supplemental information. Manufacturers must also continue to follow the requirements for the content of supplemental reports set forth in 21 CFR 803.56, meaning that for a supplemental or follow-up report, the manufacturer must:

- a. Indicate that the report being submitted is a supplemental or follow-up report;
- b. Submit the appropriate identification numbers of the report that is being updated with the supplemental information (i.e., original manufacturer report number on which the report was based); and
- c. Include only the new, changed, or corrected information.

If a manufacturer submits a summary malfunction report and subsequently becomes aware of information reasonably suggesting that an event (or events) previously submitted in a malfunction summary report represents a reportable serious injury or death event, or a new type of reportable malfunction, the manufacturer must submit an initial, individual MDR for the identified serious injury, death, or new type of reportable malfunction event within 30 calendar days of becoming aware of the additional information. The manufacturer must also simultaneously submit a supplemental report to update the initial malfunction summary report and include only the new, changed, or corrected information.<sup>24</sup>

### **C. Summary Reporting Instructions**

To meet the conditions of the VMSR Program alternative granted under 21 CFR 803.19, manufacturers of devices in eligible product codes who elect to participate in the VMSR Program must submit summary malfunction reports using the applicable sections of [Form FDA 3500A](#), which must be submitted electronically.

---

<sup>22</sup> Modification Notice, section III.B.5.

<sup>23</sup> Modification Notice, section III.F.

<sup>24</sup> Modification Notice, section III.C.

## *Contains Nonbinding Recommendations*

FDA has included an example in the the Appendix: Example Format of Malfunction Summary Reports of this guidance document.

### **(1) Instructions Using Form FDA 3500A**

Separate summary malfunction reports must be submitted for each unique combination of brand name, device model, and MDR adverse event device problem code(s).<sup>25,26</sup> We note that manufacturers must include the device identifier (DI)<sup>27</sup> portion of the unique device identifier (UDI) in each Form FDA 3500A, if available. The summary reporting instructions are the same across devices and device-led combination products.

Each summary malfunction report must include at least the following information collected on Form FDA 3500A and must be submitted in electronic format.<sup>28</sup> This information should be placed in the corresponding field of the form, as described in the form's instructions. See the Appendix for an example of where this information should be entered, using the current version of Form 3500A as of this guidance document's publication date.

- **Exemption/Variance Number** – Type in “VMSR”.
- **Describe Event or Problem** – The device event narrative must include a detailed description of the nature of the events, and, if relevant and available, we recommend including a range of patient age and weight and a breakdown of patient sex, race, and ethnicity. Inclusion of patient age, weight, sex, race, and ethnicity is not a required entry for the form; however, FDA recommends including these descriptors in a text narrative if the information is available and if a malfunction is more likely to affect a specific group of patients.
- **Brand Name** – Include the device brand name.
- **Common Device Name and Product Code** – Include the common name of the device and its product code.
- **Manufacturer Name, City, and State** – Add the manufacturer's name and identify its location. Multiple manufacturing sites could be entered in the form if the device is manufactured at multiple sites.
- **Model Number and other device identifying information** – Enter the device model and/or catalog number and lot number(s) and/or serial number(s) for the devices that are the subject of the MDR. Include any device identifier (DI) portion of the unique

---

<sup>25</sup> For more information, please see FDA website on [MDR Adverse Event Codes](#).

<sup>26</sup> Modification Notice, section III.D.

<sup>27</sup> The device identifier is a mandatory, fixed portion of a UDI that identifies the specific version or model of a device and the labeler of that device. 21 CFR 803.3.

<sup>28</sup> As described in the 2018 Notice ([83 FR 40973](#)), summary reports submitted under the VMSR Program alternative must use a specified format. On August 29, 2024, FDA issued a notification in the Federal Register, announcing a minor, technical modification to the VMSR Program alternative granted under 21 CFR 803.19, to align with the most current version of Form FDA 3500A and with current adverse event codes (Modification Notice, [89 FR 70096](#)). The instructions in this guidance regarding the summary reporting format for VMSR reports incorporate changes made in that modification. Please see the Modification Notice for more information regarding these changes.

## *Contains Nonbinding Recommendations*

device identifier<sup>29</sup> for the device version or model that is the subject of the MDR. If more than one DI is associated with the summary report and the Device Identification field cannot accommodate all associated DI information, the additional narrative field may be used to identify all other associated DIs, in addition to the other manufacturer narrative information.

- **Contact Office (and Manufacturing Site(s) for Devices)** – Enter the name, address, and email of the manufacturer reporting site (contact office), including the contact name for the summary report being submitted. Enter the name and address of the manufacturing site(s) for the device, if different from the contact office.
- **Phone Number of Contact Office** – Include a phone number for the contact office.
- **Combination Products** (if applicable) – Check if the report involves a combination product. Manufacturers may also enter other applicable information.
- **Type of Reportable Event** – Check “Malfunction.” Manufacturers must check the “Summary Report” box and identify the number of events being summarized.
- **Adverse Event Problem** – Enter the corresponding codes, including as many codes as necessary to describe the event problem and evaluation for the reportable malfunction events that are being summarized:
  - “Medical Device Problem Code”
  - “Type of Investigation”
  - “Investigation Findings”
  - “Investigation Conclusions,” even if the device was not evaluated
- **Additional Manufacturer Narrative** – Provide a summary of the results of the investigation for the reported malfunctions, including any follow up actions taken, and any additional information that would be helpful in understanding how the manufacturer addressed the malfunction events summarized in the report. Enter a breakdown of the malfunction events summarized in the report: the number of devices that were returned, the number of devices that were labeled “for single use” (if any), and the number of devices that were reprocessed and reused (if any).

## **(2) Reporting Schedule and Logistics**

To meet the conditions of the alternative established under the VMSR Program, manufacturers submitting malfunction summary reports or supplemental reports to a malfunction summary report must submit those reports electronically<sup>30</sup> on a quarterly basis according to the schedule in Table 1. The summary malfunction report must include the MDR Number, which consists of the registration number of the manufacturer, the year in which the event is being reported, and a 5-digit sequence number. Information included in a malfunction summary report must be current as of the last date of the quarterly timeframe identified in Table 1.<sup>31</sup>

All reportable malfunction events for eligible product codes may be reported in the summary format described in Section V.C of this guidance, unless the events are excluded from the scope of the VMSR Program or subject to one of the individual reporting conditions of the program

---

<sup>29</sup> For class I devices, the universal product code (UPC) may serve as the UDI (21 CFR 801.40(d)). In these instances, include the UPC.

<sup>30</sup> For more information, see the FDA website on [eMDR – Electronic Medical Device Reporting](#).

<sup>31</sup> Modification Notice, section III.F.



*Contains Nonbinding Recommendations*

(see Sections IV.B and V.A.). If a manufacturer elects to participate in the VMSR Program, the summary reports must be submitted to the FDA on a quarterly basis, according to Table 1.

**Table 1. VMSR Reporting Schedule**

<b>Reportable malfunctions that a manufacturer become aware of during these timeframes</b>	<b>Should be submitted to the FDA by</b>
January 1 – March 31	April 30
April 1 – June 30	July 31
July 1 – September 30	October 31
October 1 – December 31	January 31

## **Appendix: Example of Malfunction Summary Reports**

The following hypothetical example is solely meant to illustrate how to summarize malfunction events in summary reports under the VMSR Program. We note that the device identifiers provided are not intended to represent device identifiers that are actually assigned to any device. Real-world reporting scenarios will depend on the particular details of the malfunction(s) in question. Please note that the example provided below is solely meant to illustrate how the form might be filled out in the scenario described.

### **Multiple malfunction events with two device problems**

A manufacturer receives 50 malfunction reports within the quarterly timeframe that include two types of device malfunctions that are related to a specific model (device identifier 12345678901234) of their AC powered ABC Bed: (1) 35 events involve a tear in a disposable cover; and (2) 25 events involve a screw that attaches the bed rail to the mounting bracket on the bed, which loosens due to vibration. Ten of the events involve both types of device malfunctions. None of the events involves patients. None of the events necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health.

As stated in Section V.C.1. of this guidance, separate summary malfunction reports must be submitted for each unique combination of brand name, device model, and MDR adverse event device problem code(s). In this example, there is one brand of device and one device model (device identifier 12345678901234). There are three different combinations of adverse event codes, and therefore, three summary reports should be submitted to FDA:

Report #1: 25 events that involve torn covers only;  
Report #2: 15 events that involve loose screws only; and  
Report #3: 10 events that involve both torn covers and loose screws.

Manufacturers should note that the summary reporting format requires firms to identify the type of investigation, investigation findings and investigation conclusions codes in Form FDA 3500A, including as many codes as are necessary to describe the event problem and evaluation for the reportable malfunction events that are being summarized. If the report summarizes reportable events that involved more than one type of device problem, such as the example Report #3 described above, differences in the investigation conclusion code according to the different device problems can be explained in the narrative text.<sup>32</sup>

#### **Sample Report #1:**

- **Exemption/Variance Number:** VMSR
- **Describe Event or Problem:** This VMSR report summarizes malfunction events. A review of the events indicated that model 12345678901234 experienced a tear in a disposable cover on the AC powered beds. No patients were involved.
- **Brand Name:** ABC Bed

---

<sup>32</sup> 2018 Notice, section II.D ([83 FR 40973](#)).

### *Contains Nonbinding Recommendations*

- **Common Device Name:** AC Powered Beds
- **Product Code:** FNL
- **Manufacturer Name, City, and State:** ABC company, 123 Baker Street, Anywhere, MD, USA
- **Model Number and other device identifying information:** (01)12345678901234
- **Contact Office (and Manufacturing Site for Devices) or Compounding Outsourcing Facility:** Mr. X, ABC Company, 123 Baker Street, Anywhere, MD, USA
  - o **Phone Number:** 301-555-0001
- **Type of Reportable Event:** Malfunction, Summary Report
- **No. of events summarized:** 25
- **Adverse Event Problem (Refer to coding manual):**
  - o **Medical Device Problem Code:** 1069 (Break); 1546 (Material Rupture)
  - o **Type of Investigation:** 10 (Testing of Actual /Suspected Device)
  - o **Investigation Findings:** 170 (Manufacturing process problem identified)
  - o **Investigation Conclusions:** 12 (Cause traced to device design)
- **Additional Manufacturer Narrative:** Facilities replaced the torn covers with new ones.

### **Sample Report #2:**

- **Exemption/Variance Number:** VMSR
- **Describe Event or Problem:** This VMSR report summarizes malfunction events. A review of the events indicated that a screw that attaches the bed rail to the mounting bracket on the bed rail loosens due to vibration on model 12345678901234. The service manual for the ABC Bed instructs facility maintenance personnel to inspect these screws as part of regular preventive maintenance procedures. No patients were involved.
- **Brand Name:** ABC Bed
- **Common Device Name:** AC Powered Beds
- **Product Code:** FNL
- **Manufacturer Name, City and State:** ABC company, 123 Baker Street, Anywhere, MD, USA
- **Model Number and other device identifying information:** (01)12345678901234
- **Contact Office (and Manufacturing Site for Devices) or Compounding Outsourcing Facility:** Mr. X, ABC Company, 123 Baker Street, Anywhere, MD, USA

### *Contains Nonbinding Recommendations*

- **Phone Number:** 301-555-0001
- **Type of Reportable Event:** Malfunction, Summary Report
- **No. of events summarized:** 25
- **Adverse Event Problem (*Refer to coding manual*):**
  - **Medical Device Problem Code:** 1069 (Break2923 (Device Dislodged or Dislocated))
  - **Type of Investigation:** 10 (Testing of Actual/Suspected Device)
  - **Investigation Findings:** 170 (Manufacturing Process Problem Identified)
  - **Investigation Conclusions:** 12 (Cause Traced to Device Design)
- **Additional Manufacturer Narrative:** Facilities were given instructions on how to tighten the screw and nut. The facilities performed this maintenance and placed the ABC Beds back in service.

#### **Sample Report #3:**

- **Exemption/Variance Number:** VMSR
- **Describe Event or Problem:** This VMSR report summarizes malfunction events. A review of the events indicated that a screw that attaches the bed rail to the mounting bracket on the AC powered bed (model 12345678901234) loosened causing it to tear a disposable cover attached to the bed. The service manual for the ABC bed instructs facility maintenance personnel to inspect these screws as part of regular preventive maintenance procedures. No patients were involved.
- **Brand Name:** ABC Bed
- **Common Device Name:** AC Powered Beds
- **Product Code:** FNL
- **Manufacturer Name, City and State:** ABC Company, 123 Baker Street, Anywhere, MD, USA
- **Model Number and other device identifying information:** (01)12345678901234
- **Contact Office (*and Manufacturing Site for Devices*) or Compounding Outsourcing Facility:** Mr. X, ABC Company, 123 Baker Street, Anywhere, MD, USA
  - **Phone Number:** 301-555-0001
- **Type of Reportable Event:** Malfunction, Summary Report
- **No. of events summarized:** 25
- **Adverse Event Problem (*Refer to coding manual*):**

### *Contains Nonbinding Recommendations*

- **Medical Device Problem Code:** 1069 (Break); 1546 (Material Rupture); 2923 (Device Dislodged or Dislocated)
  - **Type of Investigation:** 10 (Testing of Actual/Suspected Device)
  - **Investigation Findings:** 170 (Manufacturing Process Problem Identified)
  - **Investigation Conclusions:** 12 (Cause Traced to Device Design)
- **Additional Manufacturer Narrative:** Technicians have examined the beds and have tightened the screw and nut. No additional torn covers have been reported by the facilities.